Roche is trading at an EV-to-NTM EBITDA multiple of 10.6x, which is closer to its historical average. Its peers like Eli Lilly, Novartis, and GlaxoSmithKline are trading at multiples of 19.5x, 12.1x, and 9.6x, respectively. The stock is trading lower than the industry average, which is close to 12.0x. However, it has always traded at such a discount to the industry average.
View more information: https://marketrealist.com/p/roche-rhhby-stock-forecast-2021/